ProCE Banner Activity

Initial Therapy for Previously Untreated Advanced HER2-Negative Gastric/GEJ Cancers

Slideset Download
Download these slides from a live webinar reviewing current and emerging therapies for untreated advanced HER2-negative gastric/GEJ cancers.

Released: July 21, 2022

Expiration: July 20, 2023

No longer available for credit.

Share

Faculty

Yelena Y. Janjigian

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant

Astellas Pharma US

Faculty Disclosure

Primary Author

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Yelena Y. Janjigian, MD: consultant/advisor: Amerisource Bergen, Arcus Biosciences, AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Geneos Therapeutics, GlaxoSmithKline, Imedex, Imugene, Lilly, Lynx Health, Merck, Merck Serono, Pfizer, Rgenix, Seagen, Silverback Therapeutics, Zymeworks; researcher: Bayer, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, NCI.